Why is The Joint Corp. (United States) ?
- RAW MATERIAL COST(Y) Fallen by -16% (YoY)
- CASH AND EQV(HY) Highest at USD 53.9 MM
- DEBT-EQUITY RATIO (HY) Lowest at -124.06 %
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -28.95%, its profits have risen by 44.8%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Along with generating -28.95% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
How much should you hold?
- Overall Portfolio exposure to The Joint Corp. (United States) should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is The Joint Corp. (United States) for you?
High Risk, Low Return
Quality key factors
Valuation Key Factors 
Technical key factors
Technical Movement
Fallen by -16% (YoY
Highest at USD 53.9 MM
Lowest at -124.06 %
At USD -0.49 MM has Grown at 83.34%
At USD -0.5 MM has Grown at 83.93%
Lowest at USD 4.75 MM
At USD 13.27 MM has Fallen at -56.15%
Lowest at 22.39 times
Lowest at USD -0.23 MM
Lowest at -1.7 %
Here's what is working for The Joint Corp. (United States)
Pre-Tax Profit (USD MM)
Net Profit (USD MM)
Cash and Cash Equivalents
Debt-Equity Ratio
Raw Material Cost as a percentage of Sales
Here's what is not working for The Joint Corp. (United States)
Net Sales (USD MM)
Operating Cash Flows (USD MM)
Operating Profit (USD MM)
Operating Profit to Sales
Debtors Turnover Ratio






